Clinical characterization of responders to first line (chemo)immunotherapy in platinumsensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).

被引：0
|
作者：
Buriolla, Silvia
Cavalieri, Stefano
Franza, Andrea
Rota, Simone
Bergamini, Cristiana
Alfieri, Salvatore
Nuzzolese, Imperia
Colombo, Elena
Ottini, Arianna
Licitra, Lisa F.
Resteghini, Carlo
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Med Oncol Unit 3, Milan, Italy
[2] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Med Oncol Unit 3, Dept Oncol & Hematooncol, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori Milano, Head & Neck Canc Med Dept, Milan, Italy
[4] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Med Oncol Unit 3, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18017
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Hsieh, Ronan W.
    Borson, Steven
    Tsagianni, Anastasia
    Zandberg, Dan P.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 146 - 151
  • [3] Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
    Park, J. C.
    Cortes, M. Useche
    Durbeck, J.
    Clark, J. R.
    Zhao, Y.
    Saladi, S. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S856
  • [4] First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
    Even, C.
    Torossian, N.
    Ibrahim, T.
    Martin, N.
    Badis, L. Mayache
    Ferrand, F. R.
    Iacob, M.
    Guigay, J.
    Le Tourneau, C.
    Daste, A.
    Saada-Bouzid, E.
    Saleh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [7] Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
    Recchia, Francesco
    Candeloro, Giampiero
    Di Staso, Mario
    Necozione, Stefano
    Bisegna, Roberta
    Bratta, Massimo
    Tombolini, Vincenzo
    Rea, Silvio
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (04) : 413 - 419
  • [8] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [9] A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC).
    Gold, Kathryn A.
    Sacco, Assuntina
    Bykowski, Julie
    Daniels, Gregory
    Pittman, Emily
    Messer, Karen
    Chen, Ruifeng
    Cohen, Ezra
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)
    Colevas, A. D.
    Kerrigan, K.
    Chin, V.
    Rainey, N.
    Park, J. J.
    Fang, B.
    Alpuim Costa, D.
    Dinis, J.
    Phan, M.
    Lin, L.
    Zhang, Y.
    Sun, S. C. C.
    Howland, M.
    Curtis, K.
    Adkins, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E85 - E86
12345